AMO ophthalmic viscosurgical device obtains CE Mark of Approval

Article

Abbott Medical Optics' Healon EndoCoat has received the European CE Mark of approval.

Abbott Medical Optics' Healon EndoCoat has received the European CE Mark of approval.

The viscous, low molecular ophthalmic viscosurgical device (OVD) is part of the Healon family and is currently available in Europe, Canada and New Zealand. The Food and Drug Administration (FDA) is presently reviewing the OVD for approval in the US.

Healon EndoCoat can be used as a surgical aid in cataract extraction, corneal transplantation and glaucoma filtration surgery and intraocular lens (IOL) implantation.

The properties of the approved OVD include the 25-gauge cannula delivery system with a guard. The OVD also lubricates and protects the eye during IOL implantation and can be combined with the original Healon OVD, Healon GVD OVD and Healon5 OVD.

Dr Donald Nixon, surgical director of TriMed Eye Center, Ontario, Canada, said: "The OVD plays an essential role in my cataract surgeries for overall endothelial cell preservation and patient safety."

Customers who presently order shipments of the Vitrax II OVD will be automatically updated to the Healon EndoCoat OVD.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.